Session Title: Free Paper Session 3: AMD I
Session Date/Time: Thursday 07/09/2017 | 08:30-10:00
Paper Time: 09:06
Venue: Room 118
First Author: : L.Sararols Ramsay SPAIN
Co Author(s): : G. Londono M. Castilla M. Bausili K. Banon M. Guarro S. Jordan
The systemic and ophthalmologic safety of intravitreal injections has been reviewed for years and confirmed by multiple multicentric studies and we now that the risk for complications is very low. Even with that we revised our retrospective data to compare the cases of retinal rhegmatogenous detachment (RRD) and retinal tears after our intravitreal injections.
Retrospective observational review
We reviewed retrospectively medical records of all intravitreal injections performed between June 2013 and March 2017 in our centre. Anti-VEGF theraphy (bevacizumab, ranibizumab and aflibercept) and dexamethasone sustained release (Ozurdex®) injections were included. Only vitreoretinal complications were evaluated retrospectively, mainly the diagnosis of rhegmatogenous retinal detachment of retinal tear
We performed 2446 injections in total, 2058 were injections performed with 30G caliber needles (bevacizumab, ranibizumab, aflibercept) and 388 were Ozurdex® dexametasone implants. There was one case of retinal detachment in Group A (30G intravitreal injections) and 3 cases in Group B (Ozurdex® implant group -22G-).
Although the vitreoretinal safety of intravitreal injections is well known, the differentiation of the caliber of the needles might have to be considered. Dexametasone implants are introduced with a 22G needle and the cylinder is then injected into the vitreous cavity; anti-VEGF medications are injected with a 30G needle and 0.05ml of liquid is injected into the vitreous cavity. Although Dexametasone implant is injected in a tunnelized incision, the traction and incarceration of the vitreous base can be considerable and that could be the cause of such a difference of RRD complications.